GeNeuro: Study Confirming the Key Role of Human Endogenous Retroviruses (HERV-K) for ALS Published in "Annals of Neurology", a Leading Scientific Journal
20 Juli 2022 - 7:30AM
Business Wire
- Online publication of HERV-K ENV's mechanism of action in
sporadic amyotrophic lateral sclerosis (ALS) leading to motor
neuron death
- This publication confirms the preclinical therapeutic effect
of GeNeuro’ s anti-HERV-K ENV antibody in neutralizing HERV-K ENV
toxicity
- Sporadic ALS is a devastating disease affecting 10,000 new
patients per year in the U.S. and Europe, with a limited survival
prognosis
Regulatory News:
GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a
biopharmaceutical company developing new treatments for
neurodegenerative and autoimmune diseases such as multiple
sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe
neuropsychiatric consequences of COVID-19 (post-COVID), announced
today the publication in the leading scientific journal "Annals of
Neurology" of the results of the collaboration between GeNeuro and
the National Institute of Neurological Disorders and Stroke
(NINDS). NINDS is part of the National Institutes of Health (NIH)
of the United States. This publication describes the novel
pathogenic mechanism of HERV-K in sporadic ALS and confirms the
action of GeNeuro's antibody to neutralize this toxicity.
The online publication (HERV-K envelope in spinal fluid of
Amyotrophic Lateral Sclerosis is toxic - Steiner et al, - Annals of
Neurology) presents preclinical data showing that HERV-K Envelope
protein leads to neuronal cell injury and death as part of an
extracellular release of the HERV-K ENV protein, and identifies the
cellular receptor targeted by this endogenous toxin. The study also
shows that the neurotoxic properties of the HERV-K ENV protein,
detected in the cerebrospinal fluid of ALS patients, are
neutralized by GeNeuro’s anti-HERV-K ENV antibody.
Dr. Hervé Perron, Scientific Director of GeNeuro, said:
"This publication highlights the results obtained through the
collaboration between NINDS and GeNeuro. It underlines the
relevance of GeNeuro's approach to sporadic ALS via its novel
monoclonal antibody that inhibits the neurotoxic effects of the
HERV-K ENV protein, an endogenous toxin detected in the
cerebrospinal fluid of patients. We now want to move forward as
quickly as possible to provide what could be a treatment that
changes the prospects for patients".
As previously mentioned, GeNeuro's preclinical development
program has enabled its anti-HERV-K ENV antibody to be humanized
and ready to enter GMP production. GeNeuro continues to be in
active discussions with potential partners for the clinical
development of the humanized antibody GNK301.
Amyotrophic lateral sclerosis (ALS), often referred to as Lou
Gehrig’s disease, is a rapidly progressing neurodegenerative
disorder characterized by the destruction of motor neurons leading
to progressive muscle paralysis. ALS affects approximately 50,000
patients worldwide, with about 10,000 new patients per year in the
United States and Europe.
About GeNeuro
GeNeuro‘s mission is to develop safe and effective treatments
against neurological disorders and autoimmune diseases, such as
multiple sclerosis, by neutralizing causal factors encoded by
HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D
facilities in Lyon, France. It owns rights to 17 patent families
protecting its technology.
For more information, visit: www.geneuro.com
https://twitter.com/GeneuroO
https://www.youtube.com/channel/UCODwH_v0z6wwnlVhGzmw0pA
https://www.linkedin.com/company/geneuro-sa/
Disclaimer:
This press release contains certain forward - looking statements
and estimates concerning GeNeuro’s financial condition, operating
results, strategy, projects and future performance and the markets
in which it operates. Such forward-looking statements and estimates
may be identified by words, such as “anticipate,” “believe,” “can,”
“could,” “estimate,” “expect,” “intend,” “is designed to,” “may,”
“might,” “plan,” “potential,” “predict,” “objective,” “should,” or
the negative of these and similar expressions. They incorporate all
topics that are not historical facts. Forward looking statements,
forecasts and estimates are based on management’s current
assumptions and assessment of risks, uncertainties and other
factors, known and unknown, which were deemed to be reasonable at
the time they were made but which may turn out to be incorrect.
Events and outcomes are difficult to predict and depend on factors
beyond the company’s control. Consequently, the actual results,
financial condition, performances and/or achievements of GeNeuro or
of the industry may turn out to differ materially from the future
results, performances or achievements expressed or implied by these
statements, forecasts and estimates. Owing to these uncertainties,
no representation is made as to the correctness or fairness of
these forward-looking statements, forecasts and estimates.
Furthermore, forward-looking statements, forecasts and estimates
speak only as of the date on which they are made, and GeNeuro
undertakes no obligation to update or revise any of them, whether
as a result of new information, future events or otherwise, except
as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220719005786/en/
GeNeuro Jesús Martin-Garcia Chairman and CEO +41 22 552
4800 investors@geneuro.com
NewCap Louis-Victor Delouvrier / Mathilde Bohin
(investors) +33 1 44 71 98 52 Arthur Rouillé (media) +33 1 44 71 94
98 geneuro@newcap.eu
GeNeuro (EU:GNRO)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
GeNeuro (EU:GNRO)
Historical Stock Chart
Von Apr 2023 bis Apr 2024